Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel.

Craddock Lee SJ, Reimer T, Garcia S, Williams EL, West M, Stuart T, Gerber DE.

J Oncol Pract. 2019 Oct 7:JOP1900315. doi: 10.1200/JOP.19.00315. [Epub ahead of print]

PMID:
31589544
2.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.

Gerber DE, Infante JR, Gordon MS, Goldberg SB, Martín M, Felip E, Martinez Garcia M, Schiller JH, Spigel DR, Cordova J, Westcott V, Wang Y, Shames DS, Choi Y, Kahn R, Dere RC, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke EW, Burris HA.

Clin Cancer Res. 2019 Sep 20. pii: clincanres.3965.2018. doi: 10.1158/1078-0432.CCR-18-3965. [Epub ahead of print]

PMID:
31540980
3.

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors.

Hsiehchen D, Watters MK, Lu R, Xie Y, Gerber DE.

JAMA Netw Open. 2019 Sep 4;2(9):e1911519. doi: 10.1001/jamanetworkopen.2019.11519.

4.

Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.

Wang S, Lai S, von Itzstein MS, Yang L, Yang DM, Zhan X, Xiao G, Halm EA, Gerber DE, Xie Y.

Cancer. 2019 Sep 10. doi: 10.1002/cncr.32377. [Epub ahead of print]

PMID:
31503336
5.

Stakeholder engagement to initiate lung cancer screening in an urban safety-net health system.

Lee SJC, Hamann HA, Browning T, Santini NO, Abbara S, Balis DS, Chiu H, Moran BA, McGuire M, Gerber DE.

Healthc (Amst). 2019 Aug 31:100370. doi: 10.1016/j.hjdsi.2019.100370. [Epub ahead of print]

PMID:
31481334
6.

Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis.

von Itzstein MS, Gupta A, Mara KC, Khanna S, Gerber DE.

Lung. 2019 Oct;197(5):593-599. doi: 10.1007/s00408-019-00255-y. Epub 2019 Jul 31.

PMID:
31367886
7.

Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

Rashdan S, Gerber DE.

Transl Lung Cancer Res. 2019 Jun;8(3):202-207. doi: 10.21037/tlcr.2018.09.15. No abstract available.

8.

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

Guo G, Gong K, Puliyapaddamba VT, Panchani N, Pan E, Mukherjee B, Damanwalla Z, Bharia S, Hatanpaa KJ, Gerber DE, Mickey BE, Patel TR, Sarkaria JN, Zhao D, Burma S, Habib AA.

Neuro Oncol. 2019 Jul 31. pii: noz127. doi: 10.1093/neuonc/noz127. [Epub ahead of print]

PMID:
31363754
9.

Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review.

Khan S, Gerber DE.

Semin Cancer Biol. 2019 Jul 19. pii: S1044-579X(19)30019-7. doi: 10.1016/j.semcancer.2019.06.012. [Epub ahead of print] Review.

PMID:
31330185
10.

Patient and provider perspectives on delivery of oral cancer therapies.

Murphy CC, Lee SJC, Gerber DE, Cox JV, Fullington HM, Higashi RT.

Patient Educ Couns. 2019 Nov;102(11):2102-2109. doi: 10.1016/j.pec.2019.06.019. Epub 2019 Jun 20.

PMID:
31239181
11.

Conceptual Model for Accrual to Cancer Clinical Trials.

Lee SJC, Murphy CC, Geiger AM, Gerber DE, Cox JV, Nair R, Skinner CS.

J Clin Oncol. 2019 Aug 10;37(23):1993-1996. doi: 10.1200/JCO.19.00101. Epub 2019 Jun 5. No abstract available.

PMID:
31166822
12.

Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer.

Wang T, Lu R, Lai S, Schiller JH, Zhou FL, Ci B, Wang S, Gao X, Yao B, Gerber DE, Johnson DH, Xiao G, Xie Y.

Cancer Inform. 2019 Apr 5;18:1176935119837547. doi: 10.1177/1176935119837547. eCollection 2019.

13.

Hyperprogressive disease: a distinct effect of immunotherapy?

Popat V, Gerber DE.

J Thorac Dis. 2019 Mar;11(Suppl 3):S262-S265. doi: 10.21037/jtd.2019.01.97. No abstract available.

14.

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

Le T, Gerber DE.

Cancers (Basel). 2019 Mar 15;11(3). pii: E366. doi: 10.3390/cancers11030366. Review.

15.

Mobile Device Applications for Electronic Patient Portals in Oncology.

Pho KK, Lu R, Gates S, Cai J, Xie D, Xie Y, Lee SJC, Gerber DE.

JCO Clin Cancer Inform. 2019 Feb;3:1-8. doi: 10.1200/CCI.18.00094.

16.

Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?

Le T, Minna JD, Gerber DE.

J Thorac Oncol. 2019 Mar;14(3):332-335. doi: 10.1016/j.jtho.2018.12.017. No abstract available.

PMID:
30782379
17.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
18.

NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.

Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg MS, Bey EA, Boothman DA.

Clin Cancer Res. 2019 Apr 15;25(8):2601-2609. doi: 10.1158/1078-0432.CCR-18-2560. Epub 2019 Jan 7.

PMID:
30617135
19.

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases.

McGehee E, Gerber DE, Reisch J, Dowell JE.

Clin Lung Cancer. 2019 Mar;20(2):e152-e157. doi: 10.1016/j.cllc.2018.11.008. Epub 2018 Nov 29. Review.

PMID:
30594459
20.

Immune dysregulation in cancer patients developing immune-related adverse events.

Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE.

Br J Cancer. 2019 Jan;120(1):63-68. doi: 10.1038/s41416-018-0155-1. Epub 2018 Oct 31.

PMID:
30377338
21.

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis.

Gerber DE, Beg MS, Fattah F, Frankel AE, Fatunde O, Arriaga Y, Dowell JE, Bisen A, Leff RD, Meek CC, Putnam WC, Kallem RR, Subramaniyan I, Dong Y, Bolluyt J, Sarode V, Luo X, Xie Y, Schwartz B, Boothman DA.

Br J Cancer. 2018 Oct;119(8):928-936. doi: 10.1038/s41416-018-0278-4. Epub 2018 Oct 15.

22.

Statistical justification of expansion cohorts in phase 1 cancer trials.

Mokdad AA, Xie XJ, Zhu H, Gerber DE, Heitjan DF.

Cancer. 2018 Aug;124(16):3339-3345. doi: 10.1002/cncr.31577. Epub 2018 Jul 5.

23.

Development and Validation of a Nomogram Prognostic Model for SCLC Patients.

Wang S, Yang L, Ci B, Maclean M, Gerber DE, Xiao G, Xie Y.

J Thorac Oncol. 2018 Sep;13(9):1338-1348. doi: 10.1016/j.jtho.2018.05.037. Epub 2018 Jun 11.

24.

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Mohamad O, Diaz de Leon A, Schroeder S, Leiker A, Christie A, Zhang-Velten E, Trivedi L, Khan S, Desai NB, Laine A, Albuquerque K, Iyengar P, Arriaga Y, Courtney K, Gerber DE, Hammers H, Choy H, Timmerman R, Brugarolas J, Hannan R.

Oncoimmunology. 2018 Mar 15;7(7):e1440168. doi: 10.1080/2162402X.2018.1440168. eCollection 2018.

25.

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

Rashdan S, Minna JD, Gerber DE.

Lancet Respir Med. 2018 Jun;6(6):472-478. doi: 10.1016/S2213-2600(18)30172-3.

PMID:
29856320
26.

Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database.

MacLean M, Luo X, Wang S, Kernstine K, Gerber DE, Xie Y.

Oncotarget. 2018 May 11;9(36):24470-24479. doi: 10.18632/oncotarget.25327. eCollection 2018 May 11.

27.

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N.

J Thorac Oncol. 2018 Sep;13(9):1363-1372. doi: 10.1016/j.jtho.2018.05.015. Epub 2018 May 23.

28.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.

Gerber DE, Horn L, Boyer M, Sanborn R, Natale R, Palmero R, Bidoli P, Bondarenko I, Germonpre P, Ghizdavescu D, Kotsakis A, Lena H, Losonczy G, Park K, Su WC, Tang M, Lai J, Kallinteris NL, Shan JS, Reck M, Spigel DR.

Ann Oncol. 2018 Jul 1;29(7):1548-1553. doi: 10.1093/annonc/mdy177.

PMID:
29767677
29.

Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis.

Yang L, Wang S, Gerber DE, Zhou Y, Xu F, Liu J, Liang H, Xiao G, Zhou Q, Gazdar A, Xie Y.

Lung Cancer. 2018 Jun;120:22-26. doi: 10.1016/j.lungcan.2018.03.011. Epub 2018 Mar 19.

PMID:
29748011
30.

Estimating lead-time bias in lung cancer diagnosis of patients with previous cancers.

Ge Z, Heitjan DF, Gerber DE, Xuan L, Pruitt SL.

Stat Med. 2018 Jul 20;37(16):2516-2529. doi: 10.1002/sim.7691. Epub 2018 Apr 23.

PMID:
29687467
31.

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer.

Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Kernstine K, Cai L, Xie Y, Zhu H, Fattah FJ, Zhang S, Takahashi M, Mukherjee B, Burma S, Dowell J, Dao K, Papadimitrakopoulou VA, Olivas V, Bivona TG, Zhao D, Habib AA.

J Clin Invest. 2018 Jun 1;128(6):2500-2518. doi: 10.1172/JCI96148. Epub 2018 May 7.

32.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Gerber DE, Socinski MA, Neal JW, Wakelee HA, Shirai K, Sequist LV, Rosovsky RP, Lilenbaum RC, Bastos BR, Huang C, Johnson ML, Hesketh PJ, Subramaniam DS, Dietrich MF, Chai F, Wang Y, Kazakin J, Schwartz B, Schiller JH, Brahmer JR, Kelly RJ.

Lung Cancer. 2018 Mar;117:44-49. doi: 10.1016/j.lungcan.2018.01.010. Epub 2018 Feb 3.

33.

Characteristics of Patients Using Patient Portals in Oncology.

Pho K, Lu R, Gates S, Xie Y, Lee SJC, Gerber DE.

JAMA Oncol. 2018 Mar 1;4(3):416-418. doi: 10.1001/jamaoncol.2017.5257. No abstract available.

34.

Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?

Gerber DE.

J Oncol Pract. 2018 Jan;14(1):32-34. doi: 10.1200/JOP.2017.028290. No abstract available.

35.

How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.

Khan SA, Pruitt SL, Xuan L, Makris U, Gerber DE.

Lung Cancer. 2018 Jan;115:97-102. doi: 10.1016/j.lungcan.2017.11.024. Epub 2017 Nov 24.

36.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Yu HA, Ahn MJ, Cho BC, Gerber DE, Natale RB, Socinski MA, Giri N, Quinn S, Sbar E, Zhang H, Giaccone G.

Lung Cancer. 2017 Oct;112:195-199. doi: 10.1016/j.lungcan.2017.08.017. Epub 2017 Aug 23.

PMID:
29191595
37.
38.

Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.

Reimer T, Lee SJC, Garcia S, Gill M, Duncan T, Williams EL, Gerber DE.

J Oncol Pract. 2017 Dec;13(12):e1021-e1029. doi: 10.1200/JOP.2017.024349. Epub 2017 Oct 13.

39.

Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.

Ning N, Yan J, Dietrich MF, Xie XJ, Gerber DE.

J Oncol Pract. 2017 Dec;13(12):e982-e991. doi: 10.1200/JOP.2017.024299. Epub 2017 Oct 11.

40.

Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, Dowell JE, Cheedella N, Nedzi L, Westover KD, Pulipparacharuvil S, Choy H, Timmerman RD.

JAMA Oncol. 2018 Jan 11;4(1):e173501. doi: 10.1001/jamaoncol.2017.3501. Epub 2018 Jan 11.

41.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

Gerber DE, Swanson P, Lopez-Chavez A, Wong L, Dowlati A, Pennell NA, Cronier DM, Qin A, Ilaria R Jr, Cosaert J, Shahir A, Baggstrom MQ.

Lung Cancer. 2017 Sep;111:108-115. doi: 10.1016/j.lungcan.2017.07.009. Epub 2017 Jul 18.

42.

Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity.

Garcia S, Bisen A, Yan J, Xie XJ, Ramalingam S, Schiller JH, Johnson DH, Gerber DE.

J Thorac Oncol. 2017 Oct;12(10):1489-1495. doi: 10.1016/j.jtho.2017.07.020. Epub 2017 Aug 9.

43.

Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.

Gerber DE, Hamann HA, Santini NO, Abbara S, Chiu H, McGuire M, Quirk L, Zhu H, Lee SJC.

Contemp Clin Trials. 2017 Sep;60:78-85. doi: 10.1016/j.cct.2017.07.003. Epub 2017 Jul 5.

PMID:
28689056
44.

A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

Rashdan S, Gerber DE.

Transl Cancer Res. 2017 Feb;6(Suppl 1):S78-S82. doi: 10.21037/tcr.2017.02.12. No abstract available.

45.

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.

Gupta A, Saltarski JM, White MA, Scaglioni PP, Gerber DE.

J Thorac Oncol. 2017 Sep;12(9):1446-1450. doi: 10.1016/j.jtho.2017.06.013. Epub 2017 Jun 21. Review.

46.

A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS.

Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J.

Oncologist. 2017 Sep;22(9):1024-e89. doi: 10.1634/theoncologist.2017-0175. Epub 2017 Jun 7.

47.

Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials.

Garcia S, Saltarski JM, Yan J, Xie XJ, Gerber DE.

Clin Lung Cancer. 2017 Nov;18(6):626-630. doi: 10.1016/j.cllc.2017.04.012. Epub 2017 May 8.

48.

Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.

Beg MS, Huang X, Silvers MA, Gerber DE, Bolluyt J, Sarode V, Fattah F, Deberardinis RJ, Merritt ME, Xie XJ, Leff R, Laheru D, Boothman DA.

J Surg Oncol. 2017 Jul;116(1):83-88. doi: 10.1002/jso.24624. Epub 2017 Mar 27.

49.

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

Le T, Sailors J, Oliver DH, Mayer M, Hoskin S, Gerber DE.

Lung Cancer. 2017 Mar;105:14-16. doi: 10.1016/j.lungcan.2017.01.005. Epub 2017 Jan 11.

50.

Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis.

Gerber DE, Beg MS, Duncan T, Gill M, Craddock Lee SJ.

Oncol Nurs Forum. 2017 Mar 1;44(2):165-170. doi: 10.1188/17.ONF.165-170.

PMID:
28222081

Supplemental Content

Loading ...
Support Center